Pay in 4 interest-free payments of $5.50 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
There are currently no approved targeted therapies for left ventricular ejection fraction (EF)-preserved heart failure (HFpEF) associated with obesity
The recommended dose is 10 billion CFU daily, taken consistently for at least four weeks to see measurable changes
Tirzepatide has demonstrated superior efficacy in both weight loss and blood glucose control compared to semaglutide (Aronne et al., 2025), highlighting the therapeutic potential of multi-agonist strategies
This occurs because the pharmacological effects supporting weight lossappetite suppression and delayed gastric emptyingcease when medication is discontinued
US$ 27.91
US$ 21.98
US$ 24.33
US$ 29.24
US$ 21.65
US$ 22.80
US$ 23.43
US$ 29.77
